Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rocket Pharmaceuticals, Inc. (RCKT : NSDQ)

• Company Description    Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. Number of Employees: 151

• Price / Volume Information    Yesterday's Closing Price: $9.06 Daily Weekly Monthly 20 Day Moving Average: 788,629 shares Shares Outstanding: 65.84 (millions) Market Capitalization: $596.49 (millions) Beta: 1.92 52 Week High: $49.66 52 Week Low: $7.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.94% -24.33% 12 Week -49.64% -45.36% Year To Date -58.50% -50.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9 CEDARBROOK DRIVE - CRANBURY,NJ 08512 USA ph: 609-659-8001 fax: 646-224-9585 investors@rocketpharma.com None

• General Corporate Information    Officers Gaurav Shah - Chief Executive Officer and Director Carlos Garcia-Parada - Chief Financial Officer John C. Militello - VP; Finance; Senior Controller and Treasurer Carsten Boess - Director Pedro Granadillo - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 77313F106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 65.84 Most Recent Split Date: 1.00 (0.25:1) Beta: 1.92 Market Capitalization: $596.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -3.08% vs. Previous Quarter: 2.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -37.21 12/31/21 - -35.41 09/30/21 - -37.93 ROA 03/31/22 - -33.99 12/31/21 - -31.62 09/30/21 - -33.28 Current Ratio 03/31/22 - 15.68 12/31/21 - 17.69 09/30/21 - 17.36 Quick Ratio 03/31/22 - 15.68 12/31/21 - 17.69 09/30/21 - 17.36 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.34 12/31/21 - 7.05 09/30/21 - 7.54 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.05 12/31/21 - 0.04 09/30/21 - 0.04 Debt-to-Capital 03/31/22 - 4.39 12/31/21 - 4.04 09/30/21 - 3.79

Powered by Zacks Investment Research ©